Compugen to release Q1 2026 financial results on May 18 with a conference call and webcast.

Compugen Ltd., a clinical-stage cancer immunotherapy company using AI/ML for drug discovery, will announce its Q1 2026 financial results on May 18 before U.S. markets open. The company will hold a conference call and webcast at 8:30 AM ET to discuss the results and provide a corporate update. Compugen is advancing multiple clinical-stage immuno-oncology programs, including COM701 and COM902 for solid tumors, and collaborates with AstraZeneca and Gilead on other therapies. Investors can access the live call via phone or webcast on Compugen's website, with a replay available afterward.